NASDAQ: NRSNNeurosense Therapeutics Ltd Stock
$1.88+0.31 (+19.75%)
Updated Jun 2, 2023
NRSN Price
$1.88
Fair Value Price
N/A
Market Cap
$22.15M
52 Week Low
$1.08
52 Week High
$4.47
P/E
-1.62x
P/B
7.67x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$13.51M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.85
Operating Cash Flow
N/A
Beta
0.57
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NRSN Overview
NeuroSense Therapeutics Ltd. is developing treatment for patients with debilitating neurodegenerative diseases.The company's lead product, PrimeC, is a novel oral formulation in clinical trials to treat amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease, and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics was incorporated in 2017 and is headquartered in Herzliya, Israel.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NRSN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NRSN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NRSN is poor value based on its book value relative to its share price (7.67x), compared to the US Biotechnology industry average (5.2x)
P/B vs Industry Valuation
NRSN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NRSN due diligence checks available for Premium users.
Be the first to know about important NRSN news, forecast changes, insider trades & much more!
NRSN News
Valuation
NRSN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.62x
Industry
11.51x
Market
52.69x
NRSN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.67x
Industry
5.2x
NRSN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NRSN's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.9M
Profit Margin
0%
Assets to liabilities
Assets
$5.3M
Liabilities
$2.4M
Debt to equity
0.85
NRSN's short-term assets ($5.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NRSN's short-term assets ($5.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NRSN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
NRSN vs Biotech Stocks
Neurosense Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.